Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
50 Years
74 Years
Male
Prostate Cancer
Trial Information
Retrospective Review of Reduce Data to Determine the Utility of PSADv While on Dutasteride for Predicting Prostate Cancer Incidence and Grade and Stage
This is a review of previously published data from a large prostate cancer prevention study
known as REDUCE that utilized a 5 ARI, dutasteride. It is the investigators intention to
review whether PSA velocity (change over time) will predict the presence of prostate cancer
and its grade and stage (severity) by two year biopsy. The investigator will review and
compare data to a previously published study of similar design with finasteride.
Inclusion Criteria:
- Men,
- 50-74 years old with elevated PSA (>=4) along with negative entry biopsy of the
prostate who had a subsequent biopsy by 24 months.
Exclusion Criteria:
- Any positive biopsy of the prostate indicative of cancer upon entry
Type of Study:
Observational
Study Design:
Observational Model: Case Control, Time Perspective: Retrospective
Principal Investigator
Steven I Cohen, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
University Urological Associates Inc.
Authority:
United States: Institutional Review Board
Study ID:
8DUT115799
NCT ID:
NCT01484808
Start Date:
January 2012
Completion Date:
May 2012
Related Keywords:
- Prostate Cancer
- PSA Density
- Prostate Cancer
- Prostate Biopsy
- PSA
- Prostatic Neoplasms
Name | Location |
|---|---|
| Division of Urology, Brown University | Providence, Rhode Island 02903 |
